Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
INC Research Holdings Inc (INCR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/27/2025: INCR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 6.26% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 81.22M USD | Price to earnings Ratio - | 1Y Target Price 33.56 |
Price to earnings Ratio - | 1Y Target Price 33.56 | ||
Volume (30-day avg) - | Beta 0.58 | 52 Weeks Range 1.17 - 2.62 | Updated Date 06/29/2025 |
52 Weeks Range 1.17 - 2.62 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.43 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -28.39% | Operating Margin (TTM) -86.82% |
Management Effectiveness
Return on Assets (TTM) -7.09% | Return on Equity (TTM) -17.03% |
Valuation
Trailing PE - | Forward PE 6.94 | Enterprise Value 120187421 | Price to Sales(TTM) 0.34 |
Enterprise Value 120187421 | Price to Sales(TTM) 0.34 | ||
Enterprise Value to Revenue 1.71 | Enterprise Value to EBITDA 5.29 | Shares Outstanding 54512600 | Shares Floating 27296363 |
Shares Outstanding 54512600 | Shares Floating 27296363 | ||
Percent Insiders 30.2 | Percent Institutions 5.38 |
Upturn AI SWOT
INC Research Holdings Inc
Company Overview
History and Background
INC Research Holdings Inc. was a global contract research organization (CRO) founded in 1985. It provided clinical development services to pharmaceutical, biotechnology, and medical device companies. It was acquired by inVentiv Health in 2017 and merged to form Syneos Health (SYNH). INC Research no longer exists as a separate publicly traded entity.
Core Business Areas
- Clinical Development: Managing and executing clinical trials across all phases of development.
- Biometrics: Providing biostatistical programming, data management, and medical writing services.
- Medical Affairs: Providing services related to medical communications and scientific affairs.
Leadership and Structure
Before its acquisition, INC Research had a typical corporate structure with a CEO, CFO, and various department heads. The organizational structure was hierarchical, with teams organized around therapeutic areas and service lines.
Top Products and Market Share
Key Offerings
- Phase I-IV Clinical Trials: Management and execution of clinical trials. Market share data is no longer applicable. Competitors would have been PPD (now Thermo Fisher Scientific), ICON, and Parexel.
- Data Management and Biostatistics: Collection, analysis, and reporting of clinical trial data. Market share data is no longer applicable. Competitors would have been the data management arms of other CROs.
Market Dynamics
Industry Overview
The CRO industry is highly competitive and driven by the increasing complexity of clinical trials, the need for efficiency and cost-effectiveness, and the growing demand for specialized expertise. Pharmaceutical and biotechnology companies increasingly outsource clinical development activities to CROs.
Positioning
Before acquisition, INC Research was a mid-sized CRO with a strong focus on therapeutic expertise and customer relationships. Its competitive advantage included therapeutic alignment and global reach.
Total Addressable Market (TAM)
The TAM for CRO services is estimated to be hundreds of billions of dollars globally. INC Research was a significant player in this market, competing for a portion of the outsourced clinical development spending.
Upturn SWOT Analysis
Strengths
- Therapeutic expertise
- Global reach
- Strong customer relationships
- Experienced management team
Weaknesses
- Smaller scale compared to larger CROs
- Reliance on key customer accounts
- Exposure to currency fluctuations
- Integration risks with acquired companies
Opportunities
- Growing demand for outsourced clinical development
- Expansion into new therapeutic areas
- Strategic partnerships with pharmaceutical companies
- Technological advancements in clinical trials
Threats
- Intense competition in the CRO industry
- Consolidation among pharmaceutical companies
- Regulatory changes and compliance requirements
- Economic downturns
Competitors and Market Share
Key Competitors
- IQV
- LH
- SYNH
- TMO
Competitive Landscape
INC Research competed on therapeutic expertise, customer service, and global capabilities. Syneos Health, the merged entity, has a broader service offering and larger scale.
Major Acquisitions
inVentiv Health
- Year: 2017
- Acquisition Price (USD millions):
- Strategic Rationale: Merge to create a leading end-to-end biopharmaceutical solutions organization.
Growth Trajectory and Initiatives
Historical Growth: INC Research grew through organic expansion and strategic acquisitions. Focus was on building expertise and expanding global reach.
Future Projections: Future projections are not applicable as INC Research is no longer an independent entity. Refer to Syneos Health analyst estimates.
Recent Initiatives: Recent Initiatives are not applicable as INC Research is no longer an independent entity.
Summary
INC Research was a mid-sized CRO known for its therapeutic expertise before being acquired by inVentiv Health to create Syneos Health. The company's strengths lay in its customer relationships and global reach, while its main challenge was competing against larger industry players. Its historical performance demonstrated consistent growth through strategic acquisitions and organic expansion, but future analysis must be directed at Syneos Health. Before the acquisition, it played a major role in the CRO business and offered its clients strong theraptic capabilities to gain market share in the space.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (historical)
- Industry reports (historical)
- Analyst reports (historical)
- Market research reports (historical)
Disclaimers:
Data is based on historical information and may not be fully accurate or complete. Analysis reflects past performance and does not guarantee future results. INC Research is no longer a separate publicly traded entity, so refer to Syneos Health for current information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About INC Research Holdings Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2014-11-07 | CEO & Chairman Mr. Alexander Rabinovich | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 320 | Website https://www.intercure.co |
Full time employees 320 | Website https://www.intercure.co | ||
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.